Phase II Trial of Outpatient Schedule of Paclitaxel in Patients with Previously Untreated Metastatic, Measurable Adenocarcinoma of the Stomach

Abstract

Paclitaxel exhibited minimal activity in this patient population.

BubR1 Is Required for a Sustained Mitotic Spindle Checkpoint Arrest in Human Cancer Cells Treated with Tubulin-Targeting Pyrrolo-1,5-Benzoxazepines

“…In support of this hypothesis, BubR1 was found to be overexpressed in a cohort of 43 gastric carcinomas (Grabsch et al, 2003). It is noteworthy that paclitaxel failed in clinical trials in patients with gastric carcinoma (Garcia et al, 2001). An overactive mitotic checkpoint may contribute to paclitaxel resistance in gastric carcinomas, among others.…”

The role of chemotherapy in the current treatment of gastric cancer

“…With paclitaxel used as a single agent, RRs of 11% and median survivals of 3 and 6.5 months have been reported [21][22][23]. In combination with 5-FU or carboplatin, trials have indicated a median survival of 9-11 months [23][24][25].…”

A phase II study of paclitaxel and capecitabine as a first-line combination chemotherapy for advanced gastric cancer

“…Paclitaxel (Taxol s ; Bristol -Meyers Squibb Company, Princeton, NJ, USA), the prototype taxane compound that interferes with tubulin assembly (Rowinsky et al, 1990), has been studied extensively in patients with previously treated or untreated gastric cancer. As a single agent, paclitaxel induced responses in 11 -17% of previously untreated patients (Ajani et al, 1998;Garcia et al, 2001), and activity was also seen in previously treated patients (Cascinu et al, 1998;Yamada et al, 2001). The in vitro cytotoxic effects of paclitaxel plus 5-FU were found to depend on the schedule used, in that application of paclitaxel before 5-FU enhanced cytotoxicity, whereas the application of paclitaxel after 5-FU resulted in a less than additive cytotoxic effect (Kano et al, 1996).…”